ARDELYX, INC. (ARDX) Stock
ARDX has an Alpha Score of 10 out of 100 (poor), computed on Nov 9, 2026 from 2 of 4 sub-scores. 6 of the hedge funds AlphaScala tracks reported ARDX in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Millennium Management's at $70.89M. Company insiders reported 0 open-market buys and 21 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
What is ARDX's Alpha Score?
How it works →Alpha Score of 10 reflects poor overall profile with poor momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own ARDX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 13.90M | $70.89M | -22% |
| Citadel Ken Griffin | 1.03M | $5.25M | -70% |
| Renaissance Technologies Jim Simons (founder) | 893K | $4.55M | -30% |
| Hussman Investment Trust John Hussman | 420K | $1.44M | n/a |
| Marshall Wace | 56K | $288.1K | -96% |
| D.E. Shaw David Shaw | 13K | $66.7K | -96% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are ARDELYX, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 21, 26 | Bishop John E | See Remarks | SELL | 17.3K | $67K |
| Aug 21, 26 | Bishop John E | See Remarks | SELL | 2.5K | $10K |
| Aug 21, 26 | Raab Michael | President & CEO | SELL | 15.0K | $58K |
| Aug 21, 26 | Raab Michael | President & CEO | SELL | 16.0K | $62K |
| Aug 21, 26 | Raab Michael | President & CEO | SELL | 8.4K | $32K |
| Aug 21, 26 | Raab Michael | President & CEO | SELL | 19.2K | $74K |
| Aug 21, 26 | Williams Laura A | Chief Patient Officer | SELL | 3.5K | $13K |
| Aug 21, 26 | Williams Laura A | Chief Patient Officer | SELL | 3.1K | $12K |
| Aug 21, 26 | Williams Laura A | Chief Patient Officer | SELL | 2.4K | $9K |
| Aug 21, 26 | Williams Laura A | Chief Patient Officer | SELL | 1.7K | $7K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are ARDX's key statistics?
Key statistics as of Oct 25, 2026
How does ARDX's valuation compare with the Healthcare sector?
| Metric | ARDX | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -12.35% | 3.66% | 170 |
| Return on equity | -36.00% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
ARDX price chart
Powered by TradingViewWhat does ARDELYX, INC. do?
Ardelyx Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class medicines to address unmet medical needs in gastrointestinal and cardio-renal diseases. The company employs an innovative platform that identifies new biological mechanisms and pathways, enabling the creation of potent therapies designed to act locally in the gastrointestinal tract, thereby minimizing systemic side effects and drug-drug interactions common with traditional treatments. Its key products include IBSRELA (tenapanor), indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH (tenapanor), used to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to or intolerance of phosphate binders. Ardelyx Inc. targets patients with significant unmet needs in these therapeutic areas, advancing patient care through targeted, efficacious treatments. Founded in 2007 and headquartered in Waltham, Massachusetts, Ardelyx Inc. plays a vital role in the biopharmaceutical sector by delivering novel solutions for challenging medical conditions.